DMD Shareholders Overwhelmingly Approve Plan of Arrangement

MONTREAL, Sept. 19, 2018 /CNW/ - DMD Digital Health Connections Group Inc. ("DMD") (NEX: DMG.H) is pleased to announce that the proposed plan of arrangement (the "Arrangement") with 10653365 Canada Inc. was overwhelmingly approved today at the annual and special meeting of shareholders of DMD (the "DMD Meeting").

DMD Shareholder Approvals

At the DMD Meeting, the special resolution authorizing the Arrangement (the "Arrangement Resolution") was approved by 169,292,694 votes out of the 199,192,947 outstanding shares of DMD. 

More specifically, the special resolution authorizing the Arrangement was approved by (i) 96.9% of the votes cast on the Arrangement Resolution by the Common Shareholders present in person or represented by proxy at the DMD Meeting, and (ii) 92.3% of the votes cast on the Arrangement Resolution by the minority shareholders present in person or represented by proxy at the DMD Meeting. The shareholders of DMD who participated in the vote represented approximately 87.7% of the issued and outstanding shares of DMD entitled to vote on the Arrangement Resolution.

DMD will make application to the Superior Court of Quebec to obtain the final order approving the Arrangement on September 24, 2018. Assuming Court approval is obtained, and other conditions of the Arrangement are satisfied or waived, the Arrangement is expected to become effective on or about October 1, 2018.

Shareholder Questions

For shareholder inquiries regarding the Arrangement, please contact Laurel Hill Advisory Group:

North America Toll Free: 1-877-452-7184
Collect Calls Outside North America: 416-304-0211
Email: [email protected]

About DMD Digital Health Connections Group Inc. ("DMD")

DMD enables pharmaceutical, pharmaceutical marketing companies, digital advertising agencies and medical device companies to reach, message, connect and interact with US physicians and healthcare professionals via multiple access channels. Its service offerings provide targeted impressions and interactions through permission-based email, targeted on-line ad-serving, and mobile app advertising channels. Several pharmaceutical companies, agencies and healthcare organizations have adopted DMD's solutions to target, engage and interact with healthcare practitioners. For more information, visit www.dmdconnects.com.

Neither NEX platform of the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE DMD Digital Health Connections Group Inc.

Laurel Hill Advisory Group: North America Toll Free: 1-877-452-7184, Collect Calls Outside North America: 416-304-0211, Email: [email protected]